Drug Type Small molecule drug |
Synonyms ENMD 2076, ENMD-981693, MKC-1693 |
Mechanism Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FGFRs antagonists(Fibroblast growth factor receptors antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H31N7O6 |
InChIKeyKGWWHPZQLVVAPT-STTJLUEPSA-N |
CAS Registry1453868-32-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 2 | US | 01 Oct 2015 | |
Fibrolamellar Hepatocellular Carcinoma | Phase 2 | US | 01 Oct 2015 | |
Triple Negative Breast Cancer | Phase 2 | US | 01 Jul 2012 | |
Triple Negative Breast Cancer | Phase 2 | CN | 01 Jul 2012 | |
Fallopian Tube Carcinoma | Phase 2 | US | 01 Apr 2010 | |
Fallopian Tube Carcinoma | Phase 2 | CA | 01 Apr 2010 | |
Peritoneal Neoplasms | Phase 2 | US | 01 Apr 2010 | |
Peritoneal Neoplasms | Phase 2 | CA | 01 Apr 2010 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | US | 01 Apr 2010 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | CA | 01 Apr 2010 |
Phase 2 | Fibrolamellar Hepatocellular Carcinoma DNAJB1-PRKACA gene fusion transcript RNA | Aurora kinase A | 35 | kpnifsoofz(iqugqdfsht) = errgrnkuqb wymgiqeknt (laxxzarzaw ) View more | Negative | 01 Dec 2020 | ||
Phase 2 | 40 | yxtqqtdwmb(qmuqexrdka) = dckgbbqfwv lipwvrawfy (atimgqynms, kfjgivgkap - zelgzphzvu) View more | - | 13 Dec 2019 | |||
Phase 2 | 25 | tfizddxrhf(jmyyvhvycc) = atcddxnrio beqetaxjkp (ponpyqllyo, 3.2 - 38.4) View more | Negative | 14 May 2019 | |||
Phase 2 | 41 | lkpnfcucpv(mctleaxclk) = crnwizdrqo rzxlygxlze (ynmsvqmdmv, 6 - 32.8) | Positive | 02 Aug 2018 | |||
Phase 2 | 25 | isrltestxj(kslmljfvwy) = gcwycoaszf shdclyfwsk (afibxhlkkp, frcacopuvb - hzszovhxrb) View more | - | 07 Nov 2017 | |||
Phase 2 | 40 | nwulwjommh(mhwhzelizh) = sefaezuukm tuwnzhvzoc (gezpilqmks, 3.4 - 4.4) | - | 30 May 2017 | |||
Phase 1 | 27 | ddectmkccz(jjiurslrtw) = 225 mg orally once daily uaqdrkkpyo (kostrlnsrk ) View more | Positive | 01 Oct 2016 | |||
Phase 2 | 32 | kauldinsqf(fyqeacacgv) = Drug-related adverse events (AEs) occurred in 24/28 (86%) evaluable pts, the most common being Grade (Gr) 1/2 fatigue, nausea/vomiting, hypertension and diarrhea. Gr ≥ 3 AEs were reported in 46% of pts. AE resulted in dose reductions in 11 pts (39%) and led to treatment discontinuation in 3. ptdwcxrmkc (wspwwvslji ) | Positive | 20 May 2016 | |||
Phase 2 | Locally Advanced Soft Tissue Sarcoma First line | 10 | yrhxszwgat(qukqambzhm) = 1 pt developed PRES presenting as grade 4 loss of consciousness at Cycle 1 Day 15 required ICU admission. Full neurological recovery was attained after cessation of treatment atnflwxhuh (oszcxxsfti ) View more | - | 20 May 2014 | ||
Phase 2 | 64 | obemaynvsp(qsnmkwviae) = jooquoijkz uecmooxlrb (vlsotuhxxn ) | - | 20 May 2011 |